Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
journal contribution
posted on 2024-09-20, 03:21authored byYi Pan, Sam Norton, James M Gwinnutt, Lianne Kearsley-Fleet, Deborah PM Symmons, Mark Lunt, Adam Young, Kimme L Hyrich, Suzanne MM Verstappen, Nicola Maiden, Tom Price, Neil Hopkinson, Sheila O'Reilly, Lesley Hordon, Ian Griffiths, Duncan Porter, Hilary Capell, Andy Hassell, Romela Benitha, Ernest Choy, David Walsh, Paul Emery, Susan Knight, Ian Bruce, Kimme Hyrich, Allister Taggart, David ScottDavid Scott, Paul Thompson, Fiona McCrae, Rhian Goodfellow, George Kitas, Ronald Jubb, Rikki Abernethy, Shane Clarke, Sandra Green, Paul Sanders, Amanda Coulson, Bev Harrison, Marwan Bukhari, Peter Klimiuk
BACKGROUND: United Kingdom guidelines for the use of biologic disease modifying anti-rheumatic drugs (bDMARDS) for rheumatoid arthritis (RA) require patients to have active disease (Disease Activity Score [DAS28] >5.1) and have failed ≥2 previous conventional synthetic DMARDs (csDMARD). Patients with moderate disease activity (MDA) do not meet these criteria, yet often have poor outcomes. This study aimed to identify trajectory groups of disability scores over three years in RA patients with MDA. METHODS: The study included biologic-naïve patients receiving csDMARDs only with MDA (3.2